Articles tagged with Protein Activation
Researchers at Howard Hughes Medical Institute have determined how P. falciparum parasites can turn on one cloaking gene and keep dozens of others silent until needed. This discovery reveals the mechanism behind the parasite's survival and has implications for developing new therapies to interfere with its immune evasion strategies.
A global signaling study suggests that cancer's genesis may be linked to the haphazard activation of secondary signaling pathways by proteins. The researchers found that only two human ErbB receptors, EGFR and ErbB2, become promiscuous when overexpressed, recruiting a large number of different signaling proteins.
The study provides conclusive evidence for the activation model of dosage compensation in flies, revealing that MSL upregulates X-linked genes twofold in males. This finding resolves a longstanding debate and highlights the importance of fine-tuning gene expression.
A study published in Neuron found that the abnormal HD protein selectively binds to and increases the level of p53 in cells, leading to increased cell death and mitochondrial dysfunction. This overactivation also causes behavioral abnormalities in mice engineered to have HD.
Scientists at Salk Institute created a mouse model to study p53 regulation in vivo, finding that chemical modifications are not essential for protein activation under stress or normal conditions. The research has implications for cancer treatment and the development of specific drugs targeting p53's negative regulators.
Researchers have identified the compound allicin as responsible for activating specific protein thermoreceptors in the mouth, leading to the characteristic burning sensation of raw garlic. This finding provides new insights into the pungency associated with raw garlic and its potential health benefits.
Researchers found that chemokines CCL19 and CCL21 induce DC maturation and enhance T-cell proliferation. Mice lacking these chemokines showed partially activated DCs, highlighting their crucial role in full maturation and proper T-cell activation.
A study published in Science identified interleukin-1Beta (IL-1â) as a major cause of severe inflammation in mouse models of Crohn's disease, which is a chronic inflammatory bowel disease affecting over 500,000 Americans. High levels of IL-1â were found in mice with mutant NOD2, a genetic defect linked to 50% of Crohn's cases.
Researchers found that Alpha-4Beta-1 is activated by CD47, causing sickle red blood cells to stick to blood vessel walls. This discovery may lead to new therapies for sickle cell disease and other anemias.
Researchers have developed a new dye that allows for direct visualization of activated proteins in living cells, enabling high-throughput drug screening. Cdc42, a key regulator of cell movement and proliferation, was visualized with the novel dye 'I-SO', which proved highly sensitive and required no protein over-expression.
Scientists have found that a longevity protein called SIRT1 delays the breakdown of axons in nerve cells, potentially slowing neurodegenerative diseases. The discovery opens new avenues for treating Parkinson's disease, Alzheimer's disease, and other disorders.
Researchers at UT Southwestern Medical Center have discovered a second chemical pathway that enhances smooth-muscle cell contraction when the primary pathway is limited. This finding has implications for treating conditions such as hypertension and other smooth muscle-related disorders.
The study reveals N-WASP activity in unexpected cellular compartments, including ruffles on the cell membrane and the nucleus. The team's new technique allows for visualization of protein activation and its integration with cellular signaling processes.
A recent study found that a sepsis drug, DAA, can significantly reduce hospital care and mortality rates among older patients. The study, which followed 386 patients over two years, showed that the drug improved survival rates and reduced the need for intensive care.
A specific group of brain proteins called alpha-Neurexins is essential for activating communication between neurons, and its absence disrupts synaptic transmission. This discovery expands knowledge of synaptic transmission and provides new insight into how the brain works.
Researchers discover that PTEN can be activated by phosphorylation, a process that counterbalances cell growth and suppresses tumor growth. This breakthrough could lead to a new therapy for cancers associated with PTEN gene mutations.
Scientists at the University of Michigan Medical School have discovered that ß-catenin can induce new hair growth in adult hair follicles. The study found that brief activation of ß-catenin in telogen-phase hair follicles is sufficient to initiate the anagen phase, leading to new hair growth within 15 days.
Researchers discovered that humanin binds to Bax, preventing its targeting to mitochondria and blocking apoptosis. This finding suggests novel therapeutic approaches to prevent diseases associated with Bax activation.
Dartmouth researchers identify a multi-tasking circadian protein called White Collar-1 that plays a critical role in regulating biological clocks. The protein is found to be both the photoreceptor and the mechanism that turns on the frequency gene, revealing a relatively simple process between light perception and gene activation.
Researchers have determined the structure of the HER3 receptor, providing a blueprint for designing new drugs that target this protein. The discovery has significant implications for cancer treatment, particularly for breast cancer patients who may benefit from alternative strategies to Herceptin.
Researchers found that certain proteasome proteins, Sug1 and Sug2, are involved in gene activation when genes are turned on. This discovery challenges conventional wisdom and could lead to a better understanding of human development and disease causes.
A recent study published in the Journal of Clinical Investigation reveals a critical role for RAGE protein in glomerular fibrosis, a major driver of chronic kidney disease. The research sheds light on potential therapeutic targets to mitigate this devastating condition.
Scientists at Rockefeller University have found that persistent activation of Stat3 protein can cause normal cells to behave like cancer cells. This discovery presents a promising new target in the fight against cancer and suggests that drugs inhibiting Stat3 activation may be effective.